Table 4.
Net reclassification improvement and integrated discrimination improvement of pediatric inflammatory bowel disease with hsCRP and with and without two molecular lipids, LacCer(d18:1/16:0) and PC(18:0p/22:6), using the prevalence of IBD (68%) in the validation cohort
| No. of patients | Reclassified (%) | |||||
|---|---|---|---|---|---|---|
| CRP+lipids classify as SC | CRP + lipids classify as IBD | Total | Downward (%) | Upward (%) | Net reclassified (%) | |
| Cases with IBD | ||||||
| CRP classifies as SC | 12 | 14 | 26 | 6% | 18% | 11% |
| CRP classifies as IBD | 5 | 49 | 54 | |||
| Total | 17 | 63 | 80 | |||
| Symptomatic controls | ||||||
| CRP classifies as SC | 25 | 1 | 26 | 16% | 3% | -14% |
| CRP classifies as IBD | 6 | 5 | 11 | |||
| Total | 31 | 6 | 37 | |||
| NRI (SE, P value) | 0.25 (0.09, P = 0.006) | |||||
| IDI (SE, P value) | 0.24 (0.04, P < 0.001) | |||||
hsCRP high sensitivity C-reactive protein; lactosyl ceramide (d18:1/16:0), LacCer(d18:1/16:0); phosphatidylcholine (18:0p/22:6), PC(18:0p/22:6); NRI net reclassification index, IDI integrated discrimination index, SE standard error.